Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer drug that has completed Phase III clinical trials to treat metabolic acidosis in patients with chronic kidney disease. The company was founded in 2013 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone415-429-7800
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees61
OptionableNot Optionable
Tricida (NASDAQ:TCDA) Frequently Asked Questions
What is Tricida's stock symbol?
Tricida trades on the NASDAQ under the ticker symbol "TCDA."
How were Tricida's earnings last quarter?
Tricida Inc (NASDAQ:TCDA) announced its quarterly earnings results on Thursday, November, 8th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.84) by $0.19. View Tricida's Earnings History.
When is Tricida's next earnings date?
What price target have analysts set for TCDA?
3 brokers have issued 12-month price objectives for Tricida's stock. Their predictions range from $32.00 to $50.00. On average, they anticipate Tricida's stock price to reach $38.6667 in the next year. This suggests a possible upside of 76.1% from the stock's current price. View Analyst Price Targets for Tricida.
What is the consensus analysts' recommendation for Tricida?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Tricida.
Has Tricida been receiving favorable news coverage?
Media coverage about TCDA stock has been trending extremely positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Tricida earned a news impact score of 4.1 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days.
Are investors shorting Tricida?
Tricida saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,827,972 shares, an increase of 64.2% from the December 14th total of 1,113,350 shares. Based on an average daily volume of 296,733 shares, the short-interest ratio is presently 6.2 days. Currently, 6.7% of the shares of the company are short sold. View Tricida's Current Options Chain.
Who are some of Tricida's key competitors?
Some companies that are related to Tricida include Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Agios Pharmaceuticals (AGIO), Emergent Biosolutions (EBS), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Akcea Therapeutics (AKCA), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD) and Reata Pharmaceuticals (RETA).
Who are Tricida's key executives?
Tricida's management team includes the folowing people:
- Dr. Gerrit Klaerner, Founder, Pres, CEO & Exec. Director (Age 47)
- Mr. Geoffrey M. Parker, CFO & Sr. VP (Age 53)
- Dr. Wilhelm Stahl, Chief Technology Officer & Sr. VP (Age 58)
- Steffen Pietzke, VP of Fin. & Chief Accounting Officer
- Jackie Cossmon, VP of Investor Relations & Communications
When did Tricida IPO?
(TCDA) raised $175 million in an IPO on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen served as the underwriters for the IPO.
When did Tricida's lock-up period expire?
Tricida's lock-up period expired on Tuesday, December 25th. Tricida had issued 11,700,000 shares in its public offering on June 28th. The total size of the offering was $222,300,000 based on an initial share price of $19.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period.
How do I buy shares of Tricida?
Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tricida's stock price today?
One share of TCDA stock can currently be purchased for approximately $21.96.
How big of a company is Tricida?
Tricida has a market capitalization of $924.67 million. Tricida employs 61 workers across the globe.
What is Tricida's official website?
How can I contact Tricida?
Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]
MarketBeat Community Rating for Tricida (NASDAQ TCDA)
MarketBeat's community ratings are surveys of what our community members think about Tricida and other stocks. Vote "Outperform" if you believe TCDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TCDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
